Immune System Evaluation of Echinacea Purpurea Root Extract in Female Harlan Sprague Dawley (Hsd:Sprague Dawley SD) Rats
Victor J. Johnsona,*, Suramya Waidyanathab, Dori R. Germolecb, Michelle C. Corab, Mark Cestab, Keith R. Shockleyc, Angela Jeffersd,
Karen Cimone, Esra Mutlub,1, Tim Cristyf, Jessica Pierfellicef, Michael I. Lustera, Gary R. Burlesona, Kristen Ryanb
a Burleson Research Technologies, Inc., Morrisville, NC, USA
b Division of Translational Toxicology, National Institute of Environmental Health Sciences, NIH, Durham, NC, USA
c Division of Intramural Research, National Institute of Environmental Health Sciences, NIH, Durham, NC, USA
d DLH, LLC, Bethesda, MD, 20817, USA
e Experimental Pathology Laboratories, Inc., Morrisville, NC, USA
f Battelle, Columbus, OH, USA
DOI: https://doi.org/10.22427/DATA-500-103-002-000-1
Publication
Abstract
Echinacea is commonly used as a dietary supplement owing to its putative anti-inflammatory, antiviral, and antibacterial activities. Unfortunately, determining risk posed to human health is challenging. A novel combination of chemical and biological characterization was employed for selection of a representative extract sample used for in vivo investigation of the immunomodulatory properties of Echinacea (E.) purpurea. In vitro cytokine profiling showed the extract could stimulate pro-inflammatory cytokine production in the absence of detectable endotoxin. An in-depth in vivo evaluation of the immune response following a 28-day oral exposure to the selected E. purpurea extract was conducted in adult Harlan Sprague Dawley (HSD) female rats at doses up to 2000 mg/kg/day. There was no evidence that E. purpurea caused overt toxicity or effects on humoral immunity. However, cell-mediated immunity was increased but only at low doses and with no evidence of a dose-response. In addition, E. purpurea treatment enhanced natural killer cell activity and the relative percentage of macrophages/monocytes in the spleen of rats from the highest treatment group. These results suggest that E. purpurea may have immunomodulatory properties that support antiviral and antibacterial activity but may also foster an immunostimulatory environment that could exacerbate some immune-mediated conditions.
Study Tables
General Toxicology Summary Tables
- I01 - Animal Removal Summary (84 KB)
- I02 - Animal Removals (1 MB)
- I03 - Growth Curve (2 MB)
- I03C - Growth Curve (1 MB)
- I04 - Mean Body Weight Summary (311 KB)
- I04G - Mean Body Weight Gain (217 KB)
- I05 - Clinical Observations Summary (89 KB)
- PA06 - Organ Weights Summary (41 KB)
Pathology
- PA02 - Incidence Rates of Neoplasms by Anatomic Site (145 KB)
- PA03 - Incidence Rates of Non-Neoplastic Lesions by Anatomic Site (157 KB)
- PA10X - Statistical Analysis of Non-Neoplastic Lesions (186 KB)
- PA46s - Summary of Gross Pathology (162 KB)
Individual Animal Data
- Anti SRBC IgM ELISpot Data (9 KB)
- Anti SRBC Serum IgM Antibody Response Data (7 KB)
- Body Weight Data (58 KB)
- Clinical Observations Data (345 KB)
- Cytotoxic T Cell Activity Data (16 KB)
- KLH TDAR Data (8 KB)
- Natural Killer Cell Activity Data (16 KB)
- Organ Weight Data (26 KB)
- Spleen Anti - CD3 Proliferation Data (13 KB)
- Spleen Antibody Forming Cell Response Data (10 KB)
- Spleen Immunophenotyping Data (14 KB)
Immunotoxicology Summary Tables
- M03 - Peripheral Blood Leukocyte Cell Differential (34 KB)
- M04 - Hematology (34 KB)
- M06 - Spleen Immunophenotyping (36 KB)
- M07 - TDAR SRBC Spleen AFC (32 KB)
- M08 - Serum IgM Antibody Titers to the T-Dependent Antigen Sheep Erythrocytes (30 KB)
- M09 - Serum Antibody Concentrations for the T-Dependent Antigen Keyhole Limpet Hemocyanin (31 KB)
- M11 - Spleen Cell Proliferative Response to Anti-CD3 Stimulation (30 KB)
- M12 - Cytotoxic T Cell Activity (31 KB)
- M15 - Natural Killer Cell Activity (30 KB)
- M19 - TDAR SRBC ELISpot (32 KB)
In vitro
- 001 In vitro Echinacea Cytokine Data_ BRT-EC1_BRT-EC2_BRT-EC13 (199 KB)
- 002 In vitro Echinacea Cytokine Data_ BRT-EC3_BRT-EC4_BRT-EC5_BRT-EC6 (259 KB)
- 003 In vitro Echinacea Cytokine Data_ BRT-EC7_BRT-EC8_BRT-EC9_BRT-EC10 (263 KB)
- 004 In vitro Echinacea Cytokine Data_ BRT-EC16_BRT-EC25_BRT-EC35_BRT-EC36 (331 KB)
- 005 In vitro Echinacea Cytokine Data_ BRT-EC11_BRT-EC12_BRT-EC14_BRT-EC34 (260 KB)
- 006 In vitro Echinacea Cytokine Data_ BRT-EC15_BRT-EC17_BRT-EC18_BRT-EC19 (251 KB)
- 007 In vitro Echinacea Cytokine Data_ BRT-EC20_BRT-EC21_BRT-EC22_BRT-EC23 (260 KB)
- 008 In vitro Echinacea Cytokine Data_ BRT-EC24_BRT-EC26_BRT-EC27_BRT-EC28 (261 KB)
- 009 In vitro Echinacea Cytokine Data_ BRT-EC29_BRT-EC30_BRT-EC31_BRT-EC32 (262 KB)
- 010 In vitro Echinacea Cytokine Data_ BRT-EC33_BRT-EC37_BRT-EC38_BRT-EC39 (260 KB)
- 011 In vitro Echinacea Cytokine Data_ BRT-EC40_BRT-EC41_BRT-EC42 (206 KB)
- Echinacea In Vitro Immunomodulation compound and donor information (20 KB)